CoChat

Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis

Open access
Geller, David E., Madge, Susan · 2011 · Respiratory Medicine
Cited by 39

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Aerosolized antibiotics are a common treatment option for patients with cystic fibrosis and chronic airway infection, as high doses can be delivered topically to the site of the infection while systemic exposure is minimized. Patients also use other aerosolized therapies (e.g. mucus-active agents, airway-wetting agents, and bronchodilators), adding significantly increase timed and complexity to their daily regimen, and often leading to lower adherence rates. A number of novel technological strategies are available that may reduce dose frequency and increase the speed of drug delivery. Psychologically based therapies may also be used to help modify behavior and thus improve adherence to treatment. Clinicians need to explore both technological and psychological strategies that will assist in the successful maintenance of treatment requirements.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0954-6111(11)70024-5

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 60

  1. Gibson, 2003, Pathophysiology and management of pulmonary infections in cystic fibrosis, Am J Respir Crit Care Med, 168, 918, 10.1164/rccm.200304-505SO · DOI · Paper page
  2. Lipuma, 2010, The changing microbial epidemiology in cystic fibrosis, Clin Microbiol Rev, 23, 299, 10.1128/CMR.00068-09 · DOI · Paper page
  3. Hauser, 2011, Clinical significance of microbial infection and adaptation in cystic fibrosis, Clin Microbiol Rev, 24, 29, 10.1128/CMR.00036-10 · DOI · Paper page
  4. Flume, 2007, Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health, Am J Respir Crit Care Med, 176, 957, 10.1164/rccm.200705-664OC · DOI · Paper page
  5. Heijerman, 2009, Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus, J Cyst Fibros, 8, 295, 10.1016/j.jcf.2009.04.005 · DOI · Paper page
  6. Moskowitz, 2008, Shifting patterns of inhaled antibiotic use in cystic fibrosis, Pediatr Pulmonol, 43, 874, 10.1002/ppul.20873 · DOI
  7. Geller, 2009, Aerosol antibiotics in cystic fibrosis, Respir Care, 54, 658, 10.4187/aarc0537 · DOI · Paper page
  8. Arias Llorente, 2008, Treatment compliance in children and adults with cystic fibrosis, J Cyst Fibros, 7, 359, 10.1016/j.jcf.2008.01.003 · DOI · Paper page
  9. Czajkowski, 1987, Medical compliance and coping with cystic fibrosis, J Child Psychol Psychiatry, 28, 311, 10.1111/j.1469-7610.1987.tb00213.x · DOI
  10. Kettler, 2002, Determinants of adherence in adults with CF, Thorax, 57, 459, 10.1136/thorax.57.5.459 · DOI · Paper page
  11. Eakin, 2011, Longitudinal association between medication adherence and lung health in people with cystic fibrosis, J Cyst Fibros, 10, 258, 10.1016/j.jcf.2011.03.005 · DOI · Paper page
  12. Rau, 2005, Determinants of patient adherence to an aerosol regimen, Respir Care, 50, 1346
  13. Milgrom, 1996, Noncompliance and treatment failure in children with asthma, J Allergy Clin Immunol, 98, 1051, 10.1016/S0091-6749(96)80190-4 · DOI · Paper page
  14. Kesser, 2009, New aerosol delivery devices for cystic fibrosis, Respir Care, 54, 754, 10.4187/002013209790983250 · DOI
  15. Geller, 2008, The science of aerosol delivery in cystic fibrosis, Pediatr Pulmonol, 43, S5, 10.1002/ppul.20860 · doi:10.1002/ppul.20860
  16. Mendelman, 1985, Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum, Am Rev Respir Dis, 132, 761
  17. King, 2010, In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis, Antimicrob Agents Chemother, 54, 143, 10.1128/AAC.00248-09 · DOI
  18. Ramsey, 1993, Efficacy of aerosolized tobramycin in patients with cystic fibrosis, N Engl J Med, 328, 1740, 10.1056/NEJM199306173282403 · DOI · Paper page
  19. Chuchalin, 2007, A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study, Paediatr Drugs, 9, 21, 10.2165/00148581-200709001-00004 · DOI
  20. Coates, 2008, Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis, Pediatr Pulmonol, 4, 753, 10.1002/ppul.20850 · DOI
  21. Dupont, 2008, A randomized, placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection, J Cyst Fibros, 7, S26, 10.1016/S1569-1993(08)60099-5 · DOI
  22. Okusanya, 2009, Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection, Antimicrob Agents Chemother, 53, 3847, 10.1128/AAC.00872-08 · DOI
  23. Bruinenberg, 2008, The effect of once-a-day inhaled liposomal ciprofloxacin hydrochloride on sputum bacterial density in cystic fibrosis patients with chronic pulmonary P. aeruginosa colonization, Pediatr Pulmonol, 43, 344
  24. Westerman, 2007, Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study, J Cyst Fibros, 6, 284, 10.1016/j.jcf.2006.10.010 · DOI
  25. Geller, 2011, Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere(tm) technology, J Aerosol Med Pulm Drug Deliv, 24, 175, 10.1089/jamp.2010.0855 · DOI · Paper page
  26. Newhouse, 2003, Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers, Chest, 124, 360, 10.1378/chest.124.1.360 · doi:10.1378/chest.124.1.360
  27. Geller, 2007, A novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety, Pediatr Pulmonol, 42, 307, 10.1002/ppul.20594 · DOI · Paper page
  28. Konstan, 2011, Tobramycin inhalation powder for Pseudomonas aeruginosa infection in cystic fibrosis: the EVOLVE trial, Pediatr Pulmonol, 46, 230, 10.1002/ppul.21356 · DOI · Paper page
  29. Konstan, 2011, Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial, J Cyst Fibros, 10, 54, 10.1016/j.jcf.2010.10.003 · DOI · Paper page
  30. Stass, 2008, Pharmacokinetics of ciprofloxacin PulmoSphere® inhalational powder, J Cyst Fibros, 7, S26, 10.1016/S1569-1993(08)60100-9 · doi:10.1016/s1569-1993(08)60100-9
  31. Tiddens, 2006, Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older, J Aerosol Med, 19, 456, 10.1089/jam.2006.19.456 · doi:10.1089/jam.2006.19.456
  32. Trapnell, 2011, Fosfomycin/tobramycin for inhalation in cystic fibrosis patients with Pseudomonas airway infection, Am J Respir Crit Care Med
  33. Yang, 2010, Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis, Pharm Res, 27, 151, 10.1007/s11095-009-9991-2 · DOI
  34. Gibson, 2006, Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis, Pediatr Pulmonol, 41, 656, 10.1002/ppul.20429 · DOI
  35. Geller, 2011, Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa, Am J Respir Crit Care Med, 183, 1510, 10.1164/rccm.201008-1293OC · DOI
  36. Hubert, 2009, Pharmacokinetics and safety of tobramycin administered by the PARI eFlow® rapid nebulizer in cystic fibrosis, J Cyst Fibros, 8, 332, 10.1016/j.jcf.2009.07.001 · doi:10.1016/j.jcf.2009.07.001
  37. Lenney, 2011, Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects, J Cyst Fibros, 10, 9, 10.1016/j.jcf.2010.08.019 · doi:10.1016/j.jcf.2010.08.019
  38. Denyer, 2010, The Adaptive Aerosol Delivery (AAD) technology: past, present, and future, J Aerosol Med Pulm Drug Deliv, 23, S1, 10.1089/jamp.2009.0791 · DOI
  39. Brand, 2000, Total deposition of therapeutic particles during spontaneous and controlled inhalations, J Pharm Sci, 89, 724, 10.1002/(SICI)1520-6017(200006)89:6<724::AID-JPS3>3.0.CO;2-B · doi:10.1002/(sici)1520-6017(200006)89:6<724::aid-jps3>3.0.co;2-b
  40. McCormack, 2011, A randomised controlled trial of breathing modes for adaptive aerosol delivery in children with cystic fibrosis, J Cyst Fibros, 10, 343, 10.1016/j.jcf.2011.04.006 · DOI
  41. Bennett, 2005, Controlled inhalation of aerosolized therapeutics, Expert Opin Drug Deliv, 2, 763, 10.1517/17425247.2.4.763 · DOI
  42. Denyer, 2010, Adherence monitoring in drug delivery, Expert Opin Drug Deliv, 7, 1127, 10.1517/17425247.2010.517520 · DOI
  43. Gibson, 1988, Perspective in parental coping with a chronically ill child: the case of cystic fibrosis, Issues Compr Pediatr Nurs, 11, 33, 10.3109/01460868809026829 · doi:10.3109/01460868809026829
  44. Madge, 2006, 'Challenges for nurses', vol. 34, 286
  45. Burker, 2004, Psychological and educational factors: better predictors of work status than FEV1 in adults with CF, Pediatr Pulmonol, 38, 413, 10.1002/ppul.20090 · DOI · Paper page
  46. Moise, 1987, Correlates of psychosocial adjustment among young adults with cystic fibrosis, J Dev Behav Pediatr, 8, 141, 10.1097/00004703-198706000-00003 · DOI
  47. Oxley, 2005, How a clinical psychologist manages the problems of adults with cystic fibrosis, J R Soc Med, 98, 37
  48. Hafetz, 2010, Child and parent perceptions of monitoring in chronic illness management: a qualitative study, Child Care Health Dev, 36, 655, 10.1111/j.1365-2214.2010.01102.x · DOI
  49. Lehane, 2007, Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper, Int J Nurs Stud, 44, 1468, 10.1016/j.ijnurstu.2006.07.010 · DOI · Paper page
  50. Abbott, 1995, Different perceptions of disease severity and self care between patients with cystic fibrosis, their close companions, and physician, Thorax, 50, 794, 10.1136/thx.50.7.794 · DOI
  51. Duff, 2010, Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: poor adherence and the need to address it, J Cyst Fibros, 9, 455, 10.1016/j.jcf.2010.08.012 · DOI
  52. Bender, 2003, Adherence intervention research: what have we learned and what do we do next?, J Allergy Clin Immunol, 112, 489, 10.1016/S0091-6749(03)01718-4 · DOI
  53. Bender, 2000, Measurement of children's asthma medication adherence by self report, mother report, canister weight, and Doser CT, Ann Allergy Asthma Immunol, 85, 416, 10.1016/S1081-1206(10)62557-4 · DOI · Paper page
  54. Elliott, 2005, Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence, Ann Pharmacother, 39, 508, 10.1345/aph.1E398 · DOI · Paper page
  55. McClimans, 2011, Health policy, patient-centred care and clinical ethics, J Eval Clin Pract, 17, 913, 10.1111/j.1365-2753.2011.01726.x · DOI
  56. Duff, 2010, Motivational interviewing for adherence problems in cystic fibrosis: state of the art review, Pediatr Pulmonol, 45, 211, 10.1002/ppul.21103 · DOI · Paper page
  57. Hides, 2011, Does the addition of integrated cognitive behaviour therapy and motivational interviewing improve the outcomes of standard care for young people with comorbid depression and substance misuse?, Med J Aust, 195, S31, 10.5694/j.1326-5377.2011.tb03263.x · DOI · Paper page
  58. Fowler, 2011, Adherence and competence assessment in studies of CBT for psychosis: current status and future directions, Epidemiol Psychiatr Sci, 20, 121, 10.1017/S2045796011000199 · DOI
  59. Brocklehurst, 2010, Personal construct psychology: a theory to help understand professional development, a philosophy to support it, Prim Dent Care, 17, 179, 10.1308/135576110792936140 · doi:10.1308/135576110792936140
  60. Melnyk, 2001, Coping in parents of children who are chronically ill: strategies for assessment and intervention, Pediatr Nurs, 27, 547

Cited by

See all 39

Metadata

Authors
Geller, D. E., & Madge, S.
Venue
Respiratory Medicine
Publisher
Elsevier BV
Published
2011-12
Volume
105
Pages
S24-S31
ISSN
0954-6111 (ISSN-L)
OpenAlex
W2027827270
Cited by
39
References
7
FWCI
2.97
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis. https://app.cochat.ai/papers/10.1016/s0954-6111(11)70024-5
The paper
Geller, D. E., & Madge, S. (2011). Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis. Respiratory Medicine. https://doi.org/10.1016/s0954-6111(11)70024-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.